Accueil   Diary - News   All news Poxel Presents Preclinical Proof-of-Concept Data

Poxel Presents Preclinical Proof-of-Concept Data

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes, and liver diseases, including non-alcoholic steatohepatitis (NASH), today announced the poster presentation of proof-of-concept data for PXL770 in a biopsy-confirmed model of diet-induced NASH at the Global NASH Congress 2018 held in London, February 26-27, 2018. The results highlight PXL770 as a novel therapeutic approach in non-alcoholic fatty liver diseases (NAFLD), improving core disease symptoms. PXL770 directly activates adenosine monophosphate-activated protein kinase (AMPK), an enzyme that controls whole-body energy metabolism, de novo lipid synthesis, fatty acid oxidation and inflammation1. PXL770 is currently being assessed in a Phase 1b multiple ascending dose study in healthy volunteers.

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to More details are available by clicking here I agree